Amundi Acquires 83,460 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Amundi grew its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 556.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 98,450 shares of the company’s stock after buying an additional 83,460 shares during the quarter. Amundi’s holdings in Dr. Reddy’s Laboratories were worth $1,556,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. POM Investment Strategies LLC increased its position in shares of Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after acquiring an additional 1,820 shares in the last quarter. Glenmede Trust Co. NA bought a new stake in shares of Dr. Reddy’s Laboratories during the third quarter valued at approximately $207,000. Sierra Ocean LLC bought a new stake in shares of Dr. Reddy’s Laboratories during the fourth quarter valued at approximately $43,000. Allworth Financial LP increased its position in shares of Dr. Reddy’s Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after acquiring an additional 2,230 shares in the last quarter. Finally, Independence Bank of Kentucky increased its position in shares of Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock valued at $44,000 after acquiring an additional 2,220 shares in the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 4.3 %

NYSE:RDY opened at $13.23 on Tuesday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12 month low of $12.50 and a 12 month high of $16.89. The company has a market cap of $11.04 billion, a PE ratio of 21.06 and a beta of 0.48. The company has a 50 day simple moving average of $13.83 and a two-hundred day simple moving average of $14.77.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on RDY. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.